Blood cancers, or haematologic cancers (e.g. leukaemia, lymphoma and myeloma), affect the production and function of blood cells and account for about one third of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and decision-makers alike. The HARMONY project aims to use ‘big data’ to deliver information that will help to improve the care of patients with these diseases. Specifically, the project will gather together, integrate and analyse anonymous patient data from a number of high quality sources. This will help the team to define clinical endpoints and outcomes for these diseases that are recognised by all key stakeholders. Meanwhile the project’s data sharing platform will facilitate and improve decision making for policy makers and clinicians alike to help them to give the right treatment to the right patient at the right time. More broadly, the project will result in a pan-European network of stakeholders with expertise in this disease area.
The project is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others.
FACTS & FIGURES
Start Date - 01/01/2017
End Date - 31/12/2021
Call IMI2 - Call 6
Grant agreement number - 116026
Type of Action: RIA (Research and Innovation Action)
IMI Funding - 20 200 000
EFPIA in kind - 19 094 265
Other - 451 352
Total Cost - 39 745 617
Project website - www.harmony-alliance.eu
Twitter - @HarmonynetEU
More information - www.imi.europa.eu/projects-results/project-factsheets/harmony